Yes, I agree that off-label use could have a sizable impact on sales of Leronlimab and we are very likely to get one or more partnerships in the coming months. They have stated such, but have also noted that they have discussions with distribution outsourcing for HIV. I interpret this along with the lowered price to be a message to GILD or other potential partners that they are not afraid of going alone.

Either way, it should be fun and interesting to watch play out over the next few months and longer term.